Growth Hormone Deficiency Epiomic Epidemiology Forecast In 19 Major Markets 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Epiomic Epidemiology Series: Growth Hormone Deficiency Forecast In 19 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.
Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland. GHD can occur at any point during an individual’s life but is primarily defined as being of childhood onset (CO) or adult onset (AO). Age at onset tends to denote a different underlying pathology for the deficiency. The majority of CO is congenital, whereas AO forms tend to be acquired or idiopathic. For congenital forms, there are three types linked with different genetic inheritance patterns. Acquired types tend to arise from a variety of tumours of the hypothalamus/pituitary as well as brain trauma, surgery/treatment of extra-cranial tumours, etc.
This report provides the current prevalent population for GHD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher’s analysis team, GHD patients grouped by various features and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Key Topics Covered:
2. Cause Of The Disease
3. Risk Factors & Prevention
4. Diagnosis Of The Disease
5. Variation By Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key Comorbid Conditions / Features Associated With The Disease
8. Methodology For Quantification Of Patient Numbers
9. Top-Line Prevalence For Growth Hormone Deficiency
10. Features Of Growth Hormone Deficiency Patients
12. Other Features
13. Comorbidities Of Growth Hormone Deficiency Patients
14. Hormonal Disturbances
15. Bone Structure Abnormalities
16. Other Comorbidities
17. Abbreviations Used In The Report
18. Other Publisher Services & Solutions
19. Reports & Publications
20. Online Epidemiology Databases
21. Online Pharmaceutical Pricing Database
For more information about this report visit https://www.researchandmarkets.com/research/kphspx/growth_hormone?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005649/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/19/2018 01:04 PM/DISC: 09/19/2018 01:04 PM